By Amanda Ernst (May 7, 2007, 12:00 AM EDT) -- Danish pharmaceutical company H. Lundbeck A/S suffered a blow Friday when a British court ruled against it in a dispute with three generic makers over a patent for its top-selling antidepressant drug, Cipralex.
The three generic companies, Teva Pharmaceuticals Ltd., Generics (UK) Ltd. and Arrow Generics Ltd., filed separate complaints alleging that certain claims in Lundbeck's Cipralex patent were invalid because they were obvious, not novel because of prior art and insufficient. The United Kingdom's High Court of Justice's Patent Court combined the three claims into one decision.
The patent in question is European Patent Number 0,347,066, titled "new enantiomers and...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!